107 related articles for article (PubMed ID: 24368529)
21. Estimation of Tumor Volumes by 11C-MeAIB and 18F-FDG PET in an Orthotopic Glioblastoma Rat Model.
Halle B; Thisgaard H; Hvidsten S; Dam JH; Aaberg-Jessen C; Thykjær AS; Høilund-Carlsen PF; Schulz MK; Andersen C; Kristensen BW
J Nucl Med; 2015 Oct; 56(10):1562-8. PubMed ID: 26229144
[TBL] [Abstract][Full Text] [Related]
22. First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy.
Oborski MJ; Laymon CM; Lieberman FS; Drappatz J; Hamilton RL; Mountz JM
Brain Behav; 2014 Mar; 4(2):312-5. PubMed ID: 24683522
[TBL] [Abstract][Full Text] [Related]
23. Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning.
Matsuo M; Miwa K; Tanaka O; Shinoda J; Nishibori H; Tsuge Y; Yano H; Iwama T; Hayashi S; Hoshi H; Yamada J; Kanematsu M; Aoyama H
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):83-9. PubMed ID: 21095072
[TBL] [Abstract][Full Text] [Related]
24. Combined imaging biomarkers for therapy evaluation in glioblastoma multiforme: correlating sodium MRI and F-18 FLT PET on a voxel-wise basis.
Laymon CM; Oborski MJ; Lee VK; Davis DK; Wiener EC; Lieberman FS; Boada FE; Mountz JM
Magn Reson Imaging; 2012 Nov; 30(9):1268-78. PubMed ID: 22819581
[TBL] [Abstract][Full Text] [Related]
25. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
Tralins KS; Douglas JG; Stelzer KJ; Mankoff DA; Silbergeld DL; Rostomily RC; Hummel S; Scharnhorst J; Krohn KA; Spence AM
J Nucl Med; 2002 Dec; 43(12):1667-73. PubMed ID: 12468518
[TBL] [Abstract][Full Text] [Related]
26. A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients.
Bollineni VR; Kramer GM; Jansma EP; Liu Y; Oyen WJ
Eur J Cancer; 2016 Mar; 55():81-97. PubMed ID: 26820682
[TBL] [Abstract][Full Text] [Related]
27. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
[TBL] [Abstract][Full Text] [Related]
28. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
[TBL] [Abstract][Full Text] [Related]
30. Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog.
Shibahara I; Kumabe T; Kanamori M; Saito R; Sonoda Y; Watanabe M; Iwata R; Higano S; Takanami K; Takai Y; Tominaga T
J Neurosurg; 2010 Aug; 113(2):358-68. PubMed ID: 19895196
[TBL] [Abstract][Full Text] [Related]
31. [18F]FLT-PET in oncology: current status and opportunities.
Been LB; Suurmeijer AJ; Cobben DC; Jager PL; Hoekstra HJ; Elsinga PH
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1659-72. PubMed ID: 15565331
[TBL] [Abstract][Full Text] [Related]
32. [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.
Been LB; Hoekstra HJ; Suurmeijer AJ; Jager PL; van der Laan BF; Elsinga PH
Oral Oncol; 2009 Dec; 45(12):e211-5. PubMed ID: 19692292
[TBL] [Abstract][Full Text] [Related]
33. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
34. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Horn KP; Yap JT; Agarwal N; Morton KA; Kadrmas DJ; Beardmore B; Butterfield RI; Boucher K; Hoffman JM
Cancer Imaging; 2015 Sep; 15(1):15. PubMed ID: 26335224
[TBL] [Abstract][Full Text] [Related]
35. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.
Idema AJ; Hoffmann AL; Boogaarts HD; Troost EG; Wesseling P; Heerschap A; van der Graaf WT; Grotenhuis JA; Oyen WJ
J Nucl Med; 2012 Dec; 53(12):1904-10. PubMed ID: 23077112
[TBL] [Abstract][Full Text] [Related]
36. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations.
Saga T; Kawashima H; Araki N; Takahashi JA; Nakashima Y; Higashi T; Oya N; Mukai T; Hojo M; Hashimoto N; Manabe T; Hiraoka M; Togashi K
Clin Nucl Med; 2006 Dec; 31(12):774-80. PubMed ID: 17117071
[TBL] [Abstract][Full Text] [Related]
38. 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria.
Bolcaen J; Acou M; Boterberg T; Vanhove C; De Vos F; Van den Broecke C; Van Holen R; Deblaere K; Goethals I
Nucl Med Commun; 2017 Mar; 38(3):242-249. PubMed ID: 27984537
[TBL] [Abstract][Full Text] [Related]
39. Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
Iagaru A; Mosci C; Mittra E; Zaharchuk G; Fischbein N; Harsh G; Li G; Nagpal S; Recht L; Gambhir SS
Radiology; 2015 Nov; 277(2):497-506. PubMed ID: 25965900
[TBL] [Abstract][Full Text] [Related]
40. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure.
Douglas JG; Stelzer KJ; Mankoff DA; Tralins KS; Krohn KA; Muzi M; Silbergeld DL; Rostomily RC; Scharnhorst J; Spence AM
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):886-91. PubMed ID: 16242251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
